MEI Pharma (FRA:MMI0) Total Long-Term Liabilities : €9.77 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is MEI Pharma Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. MEI Pharma's Total Long-Term Liabilities for the quarter that ended in Mar. 2024 was €9.77 Mil.

MEI Pharma Total Long-Term Liabilities Historical Data

The historical data trend for MEI Pharma's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma Total Long-Term Liabilities Chart

MEI Pharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Long-Term Liabilities

Get a 7-Day Free Trial

18.08

105.59

86.67

95.53

70.01

MEI Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Long-Term Liabilities	Get a 7-Day Free Trial															71.18	70.01	10.61	10.10	9.77

MEI Pharma Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

MEI Pharma Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of MEI Pharma's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

MEI Pharma (FRA:MMI0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (FRA:MMI0) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

MEIP:USA

Address

11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130

Website

https://www.meipharma.com

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

MEI Pharma (FRA:MMI0) Headlines

No Headlines